CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 4, 2019 / Oncolytics Biotech® Inc. (NASDAQ:
ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would
present at the 21st Annual BIO CEO & Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of
Oncolytics, will take place at 2:30 pm ET, on Monday, February 11, 2019, in the Herald/Soho Room at the New York Marriott
Marquis.
A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. It is recommended that listeners
log on 10 minutes in advance of the live session to register and download any necessary software. An audio replay will be
accessible approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound
induces selective tumor lysis and promotes an inflamedtumor phenotype - turning "cold" tumors "hot" - through innate and adaptive
immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may
also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies
in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a
phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and
forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements,
including the Company's belief as to the potential and mode of action of REOLYSIN, also known as pelareorep, as a cancer
therapeutic; and other statements related to anticipated developments in the Company's business and technologies involve known and
unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of pelareorep as acancer treatment, the success and timely completion of clinical
studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and
development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment.
Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements,
except as required by applicable laws.
Company Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
858-886-7813
mmoore@oncolytics.ca
Investor Relations
Timothy McCarthy
LifeSci Advisors
212.915.2564
tim@lifesciadvisors.com
Media Contact
Jason Spark
Canale Communications
619-849-6005
jason@canalecomm.com
SOURCE: Oncolytics Biotech
